FDA Clears “Any Day Dosing” Feature for Boston Scientific’s TheraSphere 360 Y90 Management Platform

March 16, 2026—Boston Scientific announced FDA clearance for the “Any Day Dosing” feature on the company’s TheraSphere 360 yttrium-90 (Y90) management platform for the treatment of liver cancer.

According to the company, the new feature gives physicians options to administer TheraSphere therapy on any day of the week. This is made possible by an additional manufacturing cycle for its Y90 glass microspheres.

In 2021, Boston Scientific announced FDA approval of the TheraSphere Y90 glass microspheres for the treatment of patients with hepatocellular carcinoma (HCC). The therapy is a targeted treatment option, including use as a bridging strategy for appropriate patients with HCC awaiting liver transplantation in the United States, noted the company.

The company explained that TheraSphere dosing is determined in part by the number of days after the microspheres are calibrated with radiation. Because radioactive Y90 decays at a predictable rate, physicians can precisely calculate and deliver the intended radiation to the tumor with precision. Historically, the microspheres have been calibrated only 1 day per week, which limited vial availability on specific days.

The additional manufacturing cycle introduces a second calibration date, which expands scheduling flexibility and enables physicians to treat on more days of the week while maintaining the intended radiation activity per microsphere and prescribed sphere count, stated Boston Scientific.